Reply from the authors of limited benefit of the new shorter MDR-TB regimen in Europe
in press
van Leth F, Guenther G, Hoffmann H, et al. Reply from the authors of limited benefit of the new shorter MDR-TB regimen in Europe. Am J Respir Crit Care Med 2017; in press [https://doi.org/10.1164/rccm.201705-0995LE].
Clinical and Laboratory Standards Institute. Wayne, CLSI
Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Wayne, CLSI, 2011.
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis
Schön T, Jureen P, Giske CG, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786–793.
Clinical characteristics and treatment outcomes of patients with low- And high-concentration isoniazid-monoresistant tuberculosis
Wang TY, Lin SM, Shie SS, et al. Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One 2014; 9: e86316.
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: A TBNET/RESIST-TB consensus statement
Domínguez J, Boettger EC, Cirillo D, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016; 20: 24–42.